English

CLEVELAND BIOLABS INC

EDGAR

CBLI Quarterly report (10-Q) · filed 2022-11-14

78 filing records in this dataset, filed from 2006-08-25 to 2022-11-14. Reported financial figures are available; chart coverage varies by period.

Inspect reported changes Compare with another company Historical disclosures Search filings Segments

Watchlist

Latest quarter

Revenue

670 thousand USD

2022 Q3 · USD

Exact inputs and evidence

Revenue: 670473 USD Source

Operating margin

-230.65%

2022 Q3 · %

Exact inputs and evidence

Operating Income: -1546442 USD Source
Revenue: 670473 USD Source

Operating cash flow

-802 thousand USD

2022 Q3 · USD

Exact inputs and evidence

Operating Cash Flow: -4731590 USD Source
Operating Cash Flow: -3930067 USD Source

Free cash flow

-802 thousand USD

2022 Q3 · USD

Exact inputs and evidence

Operating Cash Flow: -4731590 USD Source
Operating Cash Flow: -3930067 USD Source
Capital Expenditure: 6454 USD Source
Capital Expenditure: 6454 USD Source

Cash and cash equivalents: 500 thousand USD 2022-09-30 Source
Exact value

500000 USD
Long-term debt including current maturities: 0 USD 2022-09-30 Source
Exact value

0 USD
Shares outstanding: 50.7 million shares 2022-09-30 Source
Exact value

50744653 shares

Reported share-count change

58.11% · 18.6 million shares

Year-over-year change in reported shares. Splits, issuance and buybacks can affect this figure; it does not isolate employee compensation or economic dilution.

Exact inputs and evidence

32095520 shares · 2021-09-30· Source
50744653 shares · 2022-09-30· Source

Trailing twelve months

The four most recent complete quarters added together. This gives a full-year view that includes the latest quarterly results.

Capital expenditure

103 thousand USD

2021-10-01 – 2022-09-30

Exact inputs and evidence

Capital expenditure: 182970 USD · 2021-01-01 – 2021-12-31 Source
Capital expenditure: 86057 USD · 2021-01-01 – 2021-09-30 Source
Capital expenditure: 6454 USD · 2022-01-01 – 2022-03-31 Source
Capital expenditure: 6454 USD · 2022-01-01 – 2022-06-30 Source
Capital expenditure: 6454 USD · 2022-01-01 – 2022-03-31 Source
Capital expenditure: 6454 USD · 2022-01-01 – 2022-09-30 Source
Capital expenditure: 6454 USD · 2022-01-01 – 2022-06-30 Source

Includes later revisions to earlier periods. Annual charts exclude incomplete years.

Latest filing recorded: 2022-11-14.

Financial data available through: 2021-12-31.

Coverage by financial measure

Revenue: 3 of 11 periods available· newest 2021-12-31
Operating income: 10 of 11 periods available· newest 2021-12-31
Net income: 5 of 11 periods available· newest 2021-12-31
Operating cash flow: 10 of 11 periods available· newest 2021-12-31
Capital expenditure: 2 of 11 periods available· newest 2021-12-31
Total assets: 4 of 11 periods available· newest 2021-12-31
Total liabilities: 4 of 11 periods available· newest 2021-12-31
Current assets: 4 of 11 periods available· newest 2021-12-31
Current liabilities: 4 of 11 periods available· newest 2021-12-31
Cash and cash equivalents: 4 of 11 periods available· newest 2021-12-31
Long-term debt including current maturities: 2 of 11 periods available· newest 2021-12-31
Shares outstanding: 4 of 11 periods available· newest 2021-12-31

Coverage describes values retained in this snapshot. Missing values are not zero; loading limits are reported separately.

What changed year over year

Latest complete year compared with the corresponding period one year earlier. These are measured changes; they do not establish their business causes.

Revenue
+USD 1.49 million

Prior period

USD 0

2020-01-01 – 2020-12-31
Current period

USD 1.49 million

2021-01-01 – 2021-12-31

Exact inputs and evidence

1487036 − 0 = 1487036 USD

0 USD · 2020-01-01 – 2020-12-31
Inspect prior input Prior source
1487036 USD · 2021-01-01 – 2021-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Revenue · CLEVELAND BIOLABS INC · 2021-12-31 CLEVELAND BIOLABS INC (edgar:1318641) Year-over-year change in Revenue: 1487036 USD Concept: fundies:Revenue Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T11:56:01Z Snapshot: c4746d93566d4d3b9751ca19712b8be0e648b823a8a94803918d85eaf1f209aa Dimensions: Consolidated View: https://fundies.io/companies/edgar/1318641?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:Revenue: 1487036 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1318641/000143774922023703/cbli20211231_10k.htm#1067157 Filing: 000143774922023703 Input fundies:Revenue: 0 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1318641/000143774922023703/cbli20211231_10k.htm#1067875 Filing: 000143774922023703
The citation records this snapshot. The page link may show a newer release later.
Net income
−USD 89.76 million

Prior period

−USD 12.09 million

2020-01-01 – 2020-12-31
Current period

−USD 101.85 million

2021-01-01 – 2021-12-31

Exact inputs and evidence

-101850818 − -12093861 = -89756957 USD

-12093861 USD · 2020-01-01 – 2020-12-31
Inspect prior input Prior source
-101850818 USD · 2021-01-01 – 2021-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Net income · CLEVELAND BIOLABS INC · 2021-12-31 CLEVELAND BIOLABS INC (edgar:1318641) Year-over-year change in Net income: -89756957 USD Concept: fundies:NetIncome Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T11:56:01Z Snapshot: c4746d93566d4d3b9751ca19712b8be0e648b823a8a94803918d85eaf1f209aa Dimensions: Consolidated View: https://fundies.io/companies/edgar/1318641?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:NetIncome: -101850818 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1318641/000143774922023703/cbli20211231_10k.htm#1098100 Filing: 000143774922023703 Input fundies:NetIncome: -12093861 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1318641/000143774922023703/cbli20211231_10k.htm#1098888 Filing: 000143774922023703
The citation records this snapshot. The page link may show a newer release later.
Operating cash flow
−USD 23.11 million

Prior period

−USD 5.08 million

2020-01-01 – 2020-12-31
Current period

−USD 28.19 million

2021-01-01 – 2021-12-31

Exact inputs and evidence

-28193283 − -5082144 = -23111139 USD

-5082144 USD · 2020-01-01 – 2020-12-31
Inspect prior input Prior source
-28193283 USD · 2021-01-01 – 2021-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Operating cash flow · CLEVELAND BIOLABS INC · 2021-12-31 CLEVELAND BIOLABS INC (edgar:1318641) Year-over-year change in Operating cash flow: -23111139 USD Concept: fundies:OperatingCashFlow Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T11:56:01Z Snapshot: c4746d93566d4d3b9751ca19712b8be0e648b823a8a94803918d85eaf1f209aa Dimensions: Consolidated View: https://fundies.io/companies/edgar/1318641?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:OperatingCashFlow: -28193283 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1318641/000143774922023703/cbli20211231_10k.htm#1172246 Filing: 000143774922023703 Input fundies:OperatingCashFlow: -5082144 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1318641/000143774922023703/cbli20211231_10k.htm#1172976 Filing: 000143774922023703
The citation records this snapshot. The page link may show a newer release later.
Capital expenditure
+1,798.6%

Prior period

USD 9,637

2020-01-01 – 2020-12-31
Current period

USD 182,970

2021-01-01 – 2021-12-31

Exact inputs and evidence

182970 − 9637 = 173333 USD

9637 USD · 2020-01-01 – 2020-12-31
Inspect prior input Prior source
182970 USD · 2021-01-01 – 2021-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Capital expenditure · CLEVELAND BIOLABS INC · 2021-12-31 CLEVELAND BIOLABS INC (edgar:1318641) Year-over-year change in Capital expenditure: 173333 USD Concept: fundies:CapitalExpenditure Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T11:56:01Z Snapshot: c4746d93566d4d3b9751ca19712b8be0e648b823a8a94803918d85eaf1f209aa Dimensions: Consolidated View: https://fundies.io/companies/edgar/1318641?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:CapitalExpenditure: 182970 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1318641/000143774922023703/cbli20211231_10k.htm#1175230 Filing: 000143774922023703 Input fundies:CapitalExpenditure: 9637 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1318641/000143774922023703/cbli20211231_10k.htm#1175948 Filing: 000143774922023703
The citation records this snapshot. The page link may show a newer release later.

Where revenue goes

How a period’s revenue divides into costs and what remains as profit. Items marked Derived are calculated by subtraction from reported figures.

2021 2021-01-01 – 2021-12-31

Revenue USD 1.49 million 100% of revenue
Cost of revenue USD 488,314 33% of revenue
Operating expenses USD 99.34 million 6,681% of revenue
Operating income −USD 98.34 million −6,613% of revenue
Tax, interest and other Derived USD 3.51 million 236% of revenue
Net income −USD 101.85 million −6,849% of revenue

Cash

Operating cash flow −USD 28.19 million −1,896% of revenue
Capital expenditure USD 182,970 12% of revenue
Free cash flow Derived −USD 28.38 million −1,908% of revenue

Share of revenue by period

Net income
Tax, interest and other
Operating costs

2011 Operating loss: operating costs were 386% of revenue.
2020 Not shown: operating income or net income is not reported.
2021 Operating loss: operating costs were 6,713% of revenue.

Values and sources

Revenue breakdown by annual reporting period
Period	Revenue	Operating costs	Operating income	Tax, interest and other	Net income	Free cash flow	Source
2011 2011-01-01 – 2011-12-31	8790209	33895380 Derived	-25105171	-21091501 Derived	-4013670	Unavailable	Source 2011-01-01 – 2011-12-31: 8790209 USD Inspect Revenue Open source 2011-01-01 – 2011-12-31: -25105171 USD Inspect Operating Income Open source 2011-01-01 – 2011-12-31: -4013670 USD Inspect Net Income Open source 2011-01-01 – 2011-12-31: -16905390 USD Inspect Operating Cash Flow Open source
2020 2020-01-01 – 2020-12-31	0	10501668 Derived	-10501668	1592193 Derived	-12093861	-5091781 Derived	Source 2020-01-01 – 2020-12-31: 0 USD Inspect Revenue Open source 2020-01-01 – 2020-12-31: -10501668 USD Inspect Operating Income Open source 2020-01-01 – 2020-12-31: -12093861 USD Inspect Net Income Open source 2020-01-01 – 2020-12-31: -5082144 USD Inspect Operating Cash Flow Open source 2020-01-01 – 2020-12-31: 9637 USD Inspect Capital Expenditure Open source
2021 2021-01-01 – 2021-12-31	1487036	99830839 Derived	-98343803	3507015 Derived	-101850818	-28376253 Derived	Source 2021-01-01 – 2021-12-31: 1487036 USD Inspect Revenue Open source 2021-01-01 – 2021-12-31: -98343803 USD Inspect Operating Income Open source 2021-01-01 – 2021-12-31: -101850818 USD Inspect Net Income Open source 2021-01-01 – 2021-12-31: -28193283 USD Inspect Operating Cash Flow Open source 2021-01-01 – 2021-12-31: 182970 USD Inspect Capital Expenditure Open source

Amounts are exact, in USD.

Growth

Sales over time and how quickly they are changing.

Revenue

Revenue reported for each complete financial period.

USD 1.5M 2021

Values and sources

Revenue values and source evidence
Period	Series	Value(USD)	Source evidence
20112011-12-31	Revenue	8790209	Revenue: 8790209 Open source
20202020-12-31	Revenue	0	Revenue: 0 Open source
20212021-12-31	Revenue	1487036	Revenue: 1487036 Open source

Revenue growth

Change in revenue from the same financial period one year earlier.

Not enough comparable data to show this history.

Values and sources

Revenue growth values and source evidence
Period	Series	Value	Source evidence
20112011-12-31	Year over year	No prior comparable period	Revenue: 8790209 Open source
20202020-12-31	Year over year	No prior comparable period	Revenue: 0 Open source
20212021-12-31	Year over year	No prior comparable period	Revenue: 1487036 Open source Revenue: 0 Open source

Profit and cash

How much revenue becomes profit, and how much cash operations generate.

Profit margins

Operating income, net income and free cash flow as a share of revenue.

Operating margin -6,613.4% 2021

Net margin -6,849.3% 2021

Free cash flow margin -1,908.2% 2021

Operating margin
Net margin
Free cash flow margin

Values and sources

Profit margins values and source evidence
Period	Series	Value	Source evidence
20112011-12-31	Operating margin	-285.6%	Operating Income: -25105171 Open source Revenue: 8790209 Open source
20202020-12-31	Operating margin	Not reported	Operating Income: -10501668 Open source Revenue: 0 Open source
20212021-12-31	Operating margin	-6,613.4%	Operating Income: -98343803 Open source Revenue: 1487036 Open source
20112011-12-31	Net margin	-45.7%	Net Income: -4013670 Open source Revenue: 8790209 Open source
20202020-12-31	Net margin	Not reported	Net Income: -12093861 Open source Revenue: 0 Open source
20212021-12-31	Net margin	-6,849.3%	Net Income: -101850818 Open source Revenue: 1487036 Open source
20112011-12-31	Free cash flow margin	Not reported	Revenue: 8790209 Open source Operating Cash Flow: -16905390 Open source
20202020-12-31	Free cash flow margin	Not reported	Revenue: 0 Open source Operating Cash Flow: -5082144 Open source Capital Expenditure: 9637 Open source
20212021-12-31	Free cash flow margin	-1,908.2%	Revenue: 1487036 Open source Operating Cash Flow: -28193283 Open source Capital Expenditure: 182970 Open source

Operating cash flow

Cash generated by the company’s normal business operations.

USD -28.2M 2021

Values and sources

Operating cash flow values and source evidence
Period	Series	Value(USD)	Source evidence
20112011-12-31	Operating cash flow	-16905390	Operating Cash Flow: -16905390 Open source
20202020-12-31	Operating cash flow	-5082144	Operating Cash Flow: -5082144 Open source
20212021-12-31	Operating cash flow	-28193283	Operating Cash Flow: -28193283 Open source

Free cash flow

Operating cash flow minus capital expenditure for the same period and unit.

USD -28.4M 2021

Values and sources

Free cash flow values and source evidence
Period	Series	Value(USD)	Source evidence
20112011-12-31	Free cash flow	Unavailable	Operating Cash Flow: -16905390 Open source
20202020-12-31	Free cash flow	-5091781	Operating Cash Flow: -5082144 Open source Capital Expenditure: 9637 Open source
20212021-12-31	Free cash flow	-28376253	Operating Cash Flow: -28193283 Open source Capital Expenditure: 182970 Open source

Balance sheet

Liabilities and short-term ability to meet obligations at each period end.

Liabilities to assets

Total liabilities as a share of total assets.

107.1% 2021

Values and sources

Liabilities to assets values and source evidence
Period	Series	Value	Source evidence
20112011-12-31	Liabilities / assets	30.8%	Total Liabilities: 9881305 Open source Total Assets: 32126801 Open source
20202020-12-31	Liabilities / assets	453%	Total Liabilities: 4691222 Open source Total Assets: 1035484 Open source
20212021-12-31	Liabilities / assets	107.1%	Total Liabilities: 22676453 Open source Total Assets: 21169685 Open source

Current assets to current liabilities

Current assets divided by current liabilities.

0.37× 2021

Values and sources

Current assets to current liabilities values and source evidence
Period	Series	Value	Source evidence
20112011-12-31	Current assets / current liabilities	3.14×	Current Assets: 31010107 Open source Current Liabilities: 9881305 Open source
20202020-12-31	Current assets / current liabilities	0.2×	Current Assets: 925746 Open source Current Liabilities: 4620842 Open source
20212021-12-31	Current assets / current liabilities	0.37×	Current Assets: 4147343 Open source Current Liabilities: 11245250 Open source

Cash generation

Compare reported profit with operating cash and capital spending. Free cash flow is calculated as operating cash flow minus capital expenditure when both exact, consolidated amounts match the same period and unit.

Cash generation by annual reporting period
Period	Net income	Operating cash flow	Capital expenditure	Free cash flow
2011 2011-01-01 – 2011-12-31	−USD 4.01 million Exact value Exact value: -4013670 USD 2011-01-01 – 2011-12-31: -4013670 USD Inspect Net Income Open source Share or cite Citation for Net Income · CLEVELAND BIOLABS INC · 2011-12-31 CLEVELAND BIOLABS INC (edgar:1318641) Net Income: -4013670 USD Concept: fundies:NetIncome Period: 2011-01-01 to 2011-12-31 Values: Latest reported Published: 2026-11-02T11:56:01Z Snapshot: c4746d93566d4d3b9751ca19712b8be0e648b823a8a94803918d85eaf1f209aa Dimensions: Consolidated View: https://fundies.io/companies/edgar/1318641/explain?concept=fundies%3ANetIncome&period=2011-12-31&surface=latest&period_type=duration&start=2011-01-01&unit=USD&dimensions= Input fundies:NetIncome: -4013670 USD (2011-01-01 to 2011-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1318641/000119312514102607/cbli-20131231.xml#121175 Filing: 000119312514102607 The citation records this snapshot. The page link may show a newer release later.	−USD 16.91 million Exact value Exact value: -16905390 USD 2011-01-01 – 2011-12-31: -16905390 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · CLEVELAND BIOLABS INC · 2011-12-31 CLEVELAND BIOLABS INC (edgar:1318641) Operating Cash Flow: -16905390 USD Concept: fundies:OperatingCashFlow Period: 2011-01-01 to 2011-12-31 Values: Latest reported Published: 2026-11-02T11:56:01Z Snapshot: c4746d93566d4d3b9751ca19712b8be0e648b823a8a94803918d85eaf1f209aa Dimensions: Consolidated View: https://fundies.io/companies/edgar/1318641/explain?concept=fundies%3AOperatingCashFlow&period=2011-12-31&surface=latest&period_type=duration&start=2011-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -16905390 USD (2011-01-01 to 2011-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1318641/000119312514102607/cbli-20131231.xml#113394 Filing: 000119312514102607 The citation records this snapshot. The page link may show a newer release later.	Unavailable Not reported for this period.	Unavailable Free cash flow cannot be calculated because Capital expenditure is unavailable for this period.
2012 2012-01-01 – 2012-12-31	−USD 18.23 million Exact value Exact value: -18234142 USD 2012-01-01 – 2012-12-31: -18234142 USD Inspect Net Income Open source Share or cite Citation for Net Income · CLEVELAND BIOLABS INC · 2012-12-31 CLEVELAND BIOLABS INC (edgar:1318641) Net Income: -18234142 USD Concept: fundies:NetIncome Period: 2012-01-01 to 2012-12-31 Values: Latest reported Published: 2026-11-02T11:56:01Z Snapshot: c4746d93566d4d3b9751ca19712b8be0e648b823a8a94803918d85eaf1f209aa Dimensions: Consolidated View: https://fundies.io/companies/edgar/1318641/explain?concept=fundies%3ANetIncome&period=2012-12-31&surface=latest&period_type=duration&start=2012-01-01&unit=USD&dimensions= Input fundies:NetIncome: -18234142 USD (2012-01-01 to 2012-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1318641/000119312514102607/cbli-20131231.xml#809236 Filing: 000119312514102607 The citation records this snapshot. The page link may show a newer release later.	−USD 20.65 million Exact value Exact value: -20649503 USD 2012-01-01 – 2012-12-31: -20649503 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · CLEVELAND BIOLABS INC · 2012-12-31 CLEVELAND BIOLABS INC (edgar:1318641) Operating Cash Flow: -20649503 USD Concept: fundies:OperatingCashFlow Period: 2012-01-01 to 2012-12-31 Values: Latest reported Published: 2026-11-02T11:56:01Z Snapshot: c4746d93566d4d3b9751ca19712b8be0e648b823a8a94803918d85eaf1f209aa Dimensions: Consolidated View: https://fundies.io/companies/edgar/1318641/explain?concept=fundies%3AOperatingCashFlow&period=2012-12-31&surface=latest&period_type=duration&start=2012-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -20649503 USD (2012-01-01 to 2012-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1318641/000119312515067307/cbli-20141231.xml#867192 Filing: 000119312515067307 The citation records this snapshot. The page link may show a newer release later.	Unavailable Not reported for this period.	Unavailable Free cash flow cannot be calculated because Capital expenditure is unavailable for this period.
2013 2013-01-01 – 2013-12-31	−USD 17.26 million Exact value Exact value: -17262877 USD 2013-01-01 – 2013-12-31: -17262877 USD Inspect Net Income Open source Share or cite Citation for Net Income · CLEVELAND BIOLABS INC · 2013-12-31 CLEVELAND BIOLABS INC (edgar:1318641) Net Income: -17262877 USD Concept: fundies:NetIncome Period: 2013-01-01 to 2013-12-31 Values: Latest reported Published: 2026-11-02T11:56:01Z Snapshot: c4746d93566d4d3b9751ca19712b8be0e648b823a8a94803918d85eaf1f209aa Dimensions: Consolidated View: https://fundies.io/companies/edgar/1318641/explain?concept=fundies%3ANetIncome&period=2013-12-31&surface=latest&period_type=duration&start=2013-01-01&unit=USD&dimensions= Input fundies:NetIncome: -17262877 USD (2013-01-01 to 2013-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1318641/000119312514102607/cbli-20131231.xml#721771 Filing: 000119312514102607 The citation records this snapshot. The page link may show a newer release later.	−USD 23.1 million Exact value Exact value: -23102647 USD 2013-01-01 – 2013-12-31: -23102647 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · CLEVELAND BIOLABS INC · 2013-12-31 CLEVELAND BIOLABS INC (edgar:1318641) Operating Cash Flow: -23102647 USD Concept: fundies:OperatingCashFlow Period: 2013-01-01 to 2013-12-31 Values: Latest reported Published: 2026-11-02T11:56:01Z Snapshot: c4746d93566d4d3b9751ca19712b8be0e648b823a8a94803918d85eaf1f209aa Dimensions: Consolidated View: https://fundies.io/companies/edgar/1318641/explain?concept=fundies%3AOperatingCashFlow&period=2013-12-31&surface=latest&period_type=duration&start=2013-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -23102647 USD (2013-01-01 to 2013-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1318641/000119312515067307/cbli-20141231.xml#123655 Filing: 000119312515067307 The citation records this snapshot. The page link may show a newer release later.	Unavailable Not reported for this period.	Unavailable Free cash flow cannot be calculated because Capital expenditure is unavailable for this period.
2014 2014-01-01 – 2014-12-31	Unavailable Not reported for this period.	−USD 14.46 million Exact value Exact value: -14455188 USD 2014-01-01 – 2014-12-31: -14455188 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · CLEVELAND BIOLABS INC · 2014-12-31 CLEVELAND BIOLABS INC (edgar:1318641) Operating Cash Flow: -14455188 USD Concept: fundies:OperatingCashFlow Period: 2014-01-01 to 2014-12-31 Values: Latest reported Published: 2026-11-02T11:56:01Z Snapshot: c4746d93566d4d3b9751ca19712b8be0e648b823a8a94803918d85eaf1f209aa Dimensions: Consolidated View: https://fundies.io/companies/edgar/1318641/explain?concept=fundies%3AOperatingCashFlow&period=2014-12-31&surface=latest&period_type=duration&start=2014-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -14455188 USD (2014-01-01 to 2014-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1318641/000131864116000009/cbli-20151231.xml#245285 Filing: 000131864116000009 The citation records this snapshot. The page link may show a newer release later.	Unavailable Not reported for this period.	Unavailable Free cash flow cannot be calculated because Capital expenditure is unavailable for this period.
2015 2015-01-01 – 2015-12-31	Unavailable Not reported for this period.	−USD 12.08 million Exact value Exact value: -12080120 USD 2015-01-01 – 2015-12-31: -12080120 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · CLEVELAND BIOLABS INC · 2015-12-31 CLEVELAND BIOLABS INC (edgar:1318641) Operating Cash Flow: -12080120 USD Concept: fundies:OperatingCashFlow Period: 2015-01-01 to 2015-12-31 Values: Latest reported Published: 2026-11-02T11:56:01Z Snapshot: c4746d93566d4d3b9751ca19712b8be0e648b823a8a94803918d85eaf1f209aa Dimensions: Consolidated View: https://fundies.io/companies/edgar/1318641/explain?concept=fundies%3AOperatingCashFlow&period=2015-12-31&surface=latest&period_type=duration&start=2015-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -12080120 USD (2015-01-01 to 2015-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1318641/000131864117000012/cbli-20161231.xml#258263 Filing: 000131864117000012 The citation records this snapshot. The page link may show a newer release later.	Unavailable Not reported for this period.	Unavailable Free cash flow cannot be calculated because Capital expenditure is unavailable for this period.
2016 2016-01-01 – 2016-12-31	Unavailable Not reported for this period.	−USD 5.04 million Exact value Exact value: -5039639 USD 2016-01-01 – 2016-12-31: -5039639 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · CLEVELAND BIOLABS INC · 2016-12-31 CLEVELAND BIOLABS INC (edgar:1318641) Operating Cash Flow: -5039639 USD Concept: fundies:OperatingCashFlow Period: 2016-01-01 to 2016-12-31 Values: Latest reported Published: 2026-11-02T11:56:01Z Snapshot: c4746d93566d4d3b9751ca19712b8be0e648b823a8a94803918d85eaf1f209aa Dimensions: Consolidated View: https://fundies.io/companies/edgar/1318641/explain?concept=fundies%3AOperatingCashFlow&period=2016-12-31&surface=latest&period_type=duration&start=2016-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -5039639 USD (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1318641/000131864118000005/cbli-20171231.xml#167009 Filing: 000131864118000005 The citation records this snapshot. The page link may show a newer release later.	Unavailable Not reported for this period.	Unavailable Free cash flow cannot be calculated because Capital expenditure is unavailable for this period.
2017 2017-01-01 – 2017-12-31	Unavailable Not reported for this period.	−USD 6.61 million Exact value Exact value: -6611459 USD 2017-01-01 – 2017-12-31: -6611459 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · CLEVELAND BIOLABS INC · 2017-12-31 CLEVELAND BIOLABS INC (edgar:1318641) Operating Cash Flow: -6611459 USD Concept: fundies:OperatingCashFlow Period: 2017-01-01 to 2017-12-31 Values: Latest reported Published: 2026-11-02T11:56:01Z Snapshot: c4746d93566d4d3b9751ca19712b8be0e648b823a8a94803918d85eaf1f209aa Dimensions: Consolidated View: https://fundies.io/companies/edgar/1318641/explain?concept=fundies%3AOperatingCashFlow&period=2017-12-31&surface=latest&period_type=duration&start=2017-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -6611459 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1318641/000131864119000005/cbli-20181231.xml#165369 Filing: 000131864119000005 The citation records this snapshot. The page link may show a newer release later.	Unavailable Not reported for this period.	Unavailable Free cash flow cannot be calculated because Capital expenditure is unavailable for this period.
2018 2018-01-01 – 2018-12-31	Unavailable Not reported for this period.	−USD 4.61 million Exact value Exact value: -4613415 USD 2018-01-01 – 2018-12-31: -4613415 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · CLEVELAND BIOLABS INC · 2018-12-31 CLEVELAND BIOLABS INC (edgar:1318641) Operating Cash Flow: -4613415 USD Concept: fundies:OperatingCashFlow Period: 2018-01-01 to 2018-12-31 Values: Latest reported Published: 2026-11-02T11:56:01Z Snapshot: c4746d93566d4d3b9751ca19712b8be0e648b823a8a94803918d85eaf1f209aa Dimensions: Consolidated View: https://fundies.io/companies/edgar/1318641/explain?concept=fundies%3AOperatingCashFlow&period=2018-12-31&surface=latest&period_type=duration&start=2018-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -4613415 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1318641/000131864119000005/cbli-20181231.xml#165619 Filing: 000131864119000005 The citation records this snapshot. The page link may show a newer release later.	Unavailable Not reported for this period.	Unavailable Free cash flow cannot be calculated because Capital expenditure is unavailable for this period.
2020 2020-01-01 – 2020-12-31	−USD 12.09 million Exact value Exact value: -12093861 USD 2020-01-01 – 2020-12-31: -12093861 USD Inspect Net Income Open source Share or cite Citation for Net Income · CLEVELAND BIOLABS INC · 2020-12-31 CLEVELAND BIOLABS INC (edgar:1318641) Net Income: -12093861 USD Concept: fundies:NetIncome Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T11:56:01Z Snapshot: c4746d93566d4d3b9751ca19712b8be0e648b823a8a94803918d85eaf1f209aa Dimensions: Consolidated View: https://fundies.io/companies/edgar/1318641/explain?concept=fundies%3ANetIncome&period=2020-12-31&surface=latest&period_type=duration&start=2020-01-01&unit=USD&dimensions= Input fundies:NetIncome: -12093861 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1318641/000143774922023703/cbli20211231_10k.htm#1098888 Filing: 000143774922023703 The citation records this snapshot. The page link may show a newer release later.	−USD 5.08 million Exact value Exact value: -5082144 USD 2020-01-01 – 2020-12-31: -5082144 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · CLEVELAND BIOLABS INC · 2020-12-31 CLEVELAND BIOLABS INC (edgar:1318641) Operating Cash Flow: -5082144 USD Concept: fundies:OperatingCashFlow Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T11:56:01Z Snapshot: c4746d93566d4d3b9751ca19712b8be0e648b823a8a94803918d85eaf1f209aa Dimensions: Consolidated View: https://fundies.io/companies/edgar/1318641/explain?concept=fundies%3AOperatingCashFlow&period=2020-12-31&surface=latest&period_type=duration&start=2020-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -5082144 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1318641/000143774922023703/cbli20211231_10k.htm#1172976 Filing: 000143774922023703 The citation records this snapshot. The page link may show a newer release later.	USD 9,637 Exact value Exact value: 9637 USD 2020-01-01 – 2020-12-31: 9637 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · CLEVELAND BIOLABS INC · 2020-12-31 CLEVELAND BIOLABS INC (edgar:1318641) Capital Expenditure: 9637 USD Concept: fundies:CapitalExpenditure Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T11:56:01Z Snapshot: c4746d93566d4d3b9751ca19712b8be0e648b823a8a94803918d85eaf1f209aa Dimensions: Consolidated View: https://fundies.io/companies/edgar/1318641/explain?concept=fundies%3ACapitalExpenditure&period=2020-12-31&surface=latest&period_type=duration&start=2020-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 9637 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1318641/000143774922023703/cbli20211231_10k.htm#1175948 Filing: 000143774922023703 The citation records this snapshot. The page link may show a newer release later.	−USD 5.09 million Calculation and evidence -5082144 − 9637 USD Exact free cash flow: -5091781 USD 2020-01-01 – 2020-12-31: -5082144 USD · Inspect Operating Cash Flow · Source 2020-01-01 – 2020-12-31: 9637 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · CLEVELAND BIOLABS INC · 2020-12-31 CLEVELAND BIOLABS INC (edgar:1318641) Free cash flow: -5091781 USD Concept: free-cash-flow Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T11:56:01Z Snapshot: c4746d93566d4d3b9751ca19712b8be0e648b823a8a94803918d85eaf1f209aa Dimensions: Consolidated View: https://fundies.io/companies/edgar/1318641?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -5082144 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1318641/000143774922023703/cbli20211231_10k.htm#1172976 Filing: 000143774922023703 Input fundies:CapitalExpenditure: 9637 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1318641/000143774922023703/cbli20211231_10k.htm#1175948 Filing: 000143774922023703 The citation records this snapshot. The page link may show a newer release later.
2021 2021-01-01 – 2021-12-31	−USD 101.85 million Exact value Exact value: -101850818 USD 2021-01-01 – 2021-12-31: -101850818 USD Inspect Net Income Open source Share or cite Citation for Net Income · CLEVELAND BIOLABS INC · 2021-12-31 CLEVELAND BIOLABS INC (edgar:1318641) Net Income: -101850818 USD Concept: fundies:NetIncome Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T11:56:01Z Snapshot: c4746d93566d4d3b9751ca19712b8be0e648b823a8a94803918d85eaf1f209aa Dimensions: Consolidated View: https://fundies.io/companies/edgar/1318641/explain?concept=fundies%3ANetIncome&period=2021-12-31&surface=latest&period_type=duration&start=2021-01-01&unit=USD&dimensions= Input fundies:NetIncome: -101850818 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1318641/000143774922023703/cbli20211231_10k.htm#1098100 Filing: 000143774922023703 The citation records this snapshot. The page link may show a newer release later.	−USD 28.19 million Exact value Exact value: -28193283 USD 2021-01-01 – 2021-12-31: -28193283 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · CLEVELAND BIOLABS INC · 2021-12-31 CLEVELAND BIOLABS INC (edgar:1318641) Operating Cash Flow: -28193283 USD Concept: fundies:OperatingCashFlow Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T11:56:01Z Snapshot: c4746d93566d4d3b9751ca19712b8be0e648b823a8a94803918d85eaf1f209aa Dimensions: Consolidated View: https://fundies.io/companies/edgar/1318641/explain?concept=fundies%3AOperatingCashFlow&period=2021-12-31&surface=latest&period_type=duration&start=2021-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -28193283 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1318641/000143774922023703/cbli20211231_10k.htm#1172246 Filing: 000143774922023703 The citation records this snapshot. The page link may show a newer release later.	USD 182,970 Exact value Exact value: 182970 USD 2021-01-01 – 2021-12-31: 182970 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · CLEVELAND BIOLABS INC · 2021-12-31 CLEVELAND BIOLABS INC (edgar:1318641) Capital Expenditure: 182970 USD Concept: fundies:CapitalExpenditure Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T11:56:01Z Snapshot: c4746d93566d4d3b9751ca19712b8be0e648b823a8a94803918d85eaf1f209aa Dimensions: Consolidated View: https://fundies.io/companies/edgar/1318641/explain?concept=fundies%3ACapitalExpenditure&period=2021-12-31&surface=latest&period_type=duration&start=2021-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 182970 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1318641/000143774922023703/cbli20211231_10k.htm#1175230 Filing: 000143774922023703 The citation records this snapshot. The page link may show a newer release later.	−USD 28.38 million Calculation and evidence -28193283 − 182970 USD Exact free cash flow: -28376253 USD 2021-01-01 – 2021-12-31: -28193283 USD · Inspect Operating Cash Flow · Source 2021-01-01 – 2021-12-31: 182970 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · CLEVELAND BIOLABS INC · 2021-12-31 CLEVELAND BIOLABS INC (edgar:1318641) Free cash flow: -28376253 USD Concept: free-cash-flow Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T11:56:01Z Snapshot: c4746d93566d4d3b9751ca19712b8be0e648b823a8a94803918d85eaf1f209aa Dimensions: Consolidated View: https://fundies.io/companies/edgar/1318641?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -28193283 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1318641/000143774922023703/cbli20211231_10k.htm#1172246 Filing: 000143774922023703 Input fundies:CapitalExpenditure: 182970 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1318641/000143774922023703/cbli20211231_10k.htm#1175230 Filing: 000143774922023703 The citation records this snapshot. The page link may show a newer release later.

Capital expenditure uses the canonical mapped positive-spending convention. A missing, ambiguous, incompatible, or negative-sign input is left blank. Values use the latest reported version.

Dataset coverage and company identifiers

Coverage reflects filings processed into this Fundies dataset; it does not imply every source filing is loaded.

78 filings · 3,480 latest values · 3,480 originally reported values

Dataset published 2026-11-02. Source filing dates and reporting periods are shown separately.

Identifiers: 0001318641, 1318641, CBLI, STAB, cbli, edgar:1318641

Also known as CLEVELAND BIOLABS INC, Cytocom Inc., Cytocom, Inc., Statera Biopharma, Inc (fka Cytocom Inc), Statera Biopharma, Inc.

CLEVELAND BIOLABS INC

Latest quarter

Revenue

Operating margin

Operating cash flow

Free cash flow

Reported share-count change

Trailing twelve months

Capital expenditure

Company performance

What changed year over year

Revenue

Net income

Operating cash flow

Capital expenditure

Where revenue goes

2021 2021-01-01 – 2021-12-31

Cash

Share of revenue by period

Growth

Profit and cash

Balance sheet

Cash generation